Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Argus Health
Merck
Harvard Business School
Covington
Federal Trade Commission
Julphar
Cantor Fitzgerald
US Army

Generated: June 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,940,328

« Back to Dashboard

Which drugs does patent 8,940,328 protect, and when does it expire?

Patent 8,940,328 protects APRISO and is included in one NDA.

This patent has ten patent family members in nine countries.
Summary for Patent: 8,940,328
Title:Pellet formulation for the treatment of the intestinal tract
Abstract: An orally administrable pharmaceutical pellet formulation for the treatment of the intestinal tract is disclosed, which comprises a core and an enteric coating, the core including, as a pharmaceutical active compound, aminosalicylic acid or a pharmaceutically tolerable salt or a derivative thereof.
Inventor(s): Otterbeck; Norbert (Uberlingen, DE), Gruber; Peter (Merzhausen, DE)
Assignee: Dr. Falk Pharma GmbH (Freiburg, DE)
Application Number:13/790,809
Patent Claim Types:
see list of patent claims
Use; Formulation; Compound; Dosage form; Process;

Drugs Protected by US Patent 8,940,328

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Valeant Pharms Intl APRISO mesalamine CAPSULE, EXTENDED RELEASE;ORAL 022301-001 Oct 31, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,940,328

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,337,886 Pellet formulation for the treatment of the intestinal tract ➤ Try a Free Trial
8,911,778 Pellet formulation for the treatment of the intestinal tract ➤ Try a Free Trial
8,956,647 Pellet formulation for the treatment of the intestinal tract ➤ Try a Free Trial
6,277,412 Pellet-type formulation intended for treating the intestinal tract ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 8,940,328

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 241964 ➤ Try a Free Trial
Canada 2297832 ➤ Try a Free Trial
Germany 19732903 ➤ Try a Free Trial
Germany 59808642 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Federal Trade Commission
Fuji
AstraZeneca
Queensland Health
US Department of Justice
Covington
Express Scripts
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.